Technology Platform

Genome Editing and Epigenetic Modification Platform、Ex vivo Rapid Expansion Platform、Ex vivo Rapid Evaluation Platform for Cell Therapeutics、Non-viral Transfection Platform

Genome Editing and Epigenetic Modification Platform

Using CRISPR editing technology, we can edit and modify the DNA or RNA of human ···

View more
Genome Editing and Epigenetic Modification Platform Genome Editing and Epigenetic Modification Platform

In vitro rapid amplification platform

Rapid large-scale culture of immune cells (T cells and NK cells) and stem cells ···

View more
In vitro rapid amplification platform In vitro rapid amplification platform

In vitro rapid assessment platform for cellular drugs

A rapid in vitro evaluation system utilizing multidisciplinary technologies such···

View more
In vitro rapid assessment platform for cellular drugs In vitro rapid assessment platform for cellular drugs

About Us

Innovating biotechnology for the betterment of human health.

Chengdu MedGenCell Co., Ltd

ChengduMedGenCellCo.,Ltd (hereafter referred to as "the Company") was established in 2015. It is a technology enterprise primarily engaged in the research and development of cutting-edge pre...

  • 2015

    Established in 2015
    • Chengdu MedGenCell Co., Ltd

  • 700+

    700 sq ft GMP laboratory
    • Chengdu MedGenCell Co., Ltd

  • 20+

    Core R&D Team
    • Chengdu MedGenCell Co., Ltd

  • 4Item

    Pipeline under development
    • Chengdu MedGenCell Co., Ltd

  • 2Vice

    Access to top provincial/city innovation and entrepreneurship teams
    • Chengdu MedGenCell Co., Ltd

  • 10+

    National Invention Patent
    • Chengdu MedGenCell Co., Ltd
    Chengdu MedGenCell Co., Ltd

    HONORARY QUALIFICATION

    Awards and Qualifications

    News

    12-11

    Good News | Group Standard "Guidelines for Gene Editing Technology Based on the CRISPR/Cas System", Co-Drafted by Chengdu MedGenCell, Officially Released

    Latest news from the China Inspection and Testing Society: The Guidelines for Gene Editing Technolog···
    10-11

    Good News | The National Standard "Biotechnology—Genome editing—Part 1: Vocabulary", which Chengdu MedGenCell participated in drafting, has been formally released.

    Warmest congratulations! Recently, the national standard GB/T 46433.1-2025 "Biotechnology—Genome ed···
    09-01

    【Recruitment】Late-stage non-small cell lung cancer trial participants sought

    Recruitment of participants with advanced non-small cell lung cancer
    08-20

    Good news | The "Quality Control Standards for Immune Cell Therapy Products" drafted by Chengdu MedGenCell has been officially released

    In April this year, Chengdu MedGenCell received good news from the China Inspection and Testing Asso···
    07-23

    「Ride the Summer Waves, Paddle as One」

    Summer has arrived, in order to enhance team cohesion, Chengdu MedGenCell specially planned 「Ride t···
    07-14

    Taiwan experts and scholars and Mengjiang Investment Group leaders visited Chengdu MedGenCell to explore the application and industrialisation of cellular and exosome technologies

    Recently, Chengdu MedGenCell was honoured to receive a group of scholars consisting of 6 experts in ···
    More